Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
Go back to Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks| (NASDAQ: PHVS) | Delayed: 36.37 -1.63 (4.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $38.00 | 52 Week High | $ | |||
| Open | $38.09 | 52 Week Low | $ | |||
| Day High | $38.20 | P/E | N/A | |||
| Day Low | $36.08 | EPS | $ | |||
| Volume | 580,260 | |||||
